A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223

被引:779
|
作者
Wang, Kun [1 ]
Long, Bo [2 ,3 ]
Liu, Fang [4 ]
Wang, Jian-Xun [1 ]
Liu, Cui-Yun [1 ]
Zhao, Bing [1 ]
Zhou, Lu-Yu [1 ]
Sun, Teng [1 ]
Wang, Man [1 ]
Yu, Tao [1 ]
Gong, Ying [1 ]
Liu, Jia [1 ]
Dong, Yan-Han [1 ]
Li, Na [1 ]
Li, Pei-Feng [1 ]
机构
[1] Qingdao Univ, Inst Translat Med, Coll Med, Ctr Dev Cardiol, Qingdao 266021, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Cent Res Lab, Lab Mol Med, Beijing 100730, Peoples R China
[3] Peking Union Med Coll, Beijing 100730, Peoples R China
[4] Guilin Med Univ, Dept Anat, Coll Basic Med, Guilin 541004, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Circular RNA; HRCR; Cardiac hypertrophy; Heart failure; CASPASE RECRUITMENT DOMAIN; MUSCLE-SPECIFIC MICRORNA; CARDIAC-HYPERTROPHY; APOPTOSIS REPRESSOR; CARDIOMYOCYTE HYPERTROPHY; CELL PROLIFERATION; SKELETAL-MUSCLE; DIFFERENTIATION; OVEREXPRESSION; TRANSCRIPTS;
D O I
10.1093/eurheartj/ehv713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our present study reveals a novel cardiac hypertrophic regulating model that is composed of circRNA, miR-223, and ARC. Modulation of their levels may provide a new approach for tackling cardiac hypertrophy and heart failure. Our present work advances our understanding about the role of circRNAs and miRNAs in cardiac hypertrophy and heart failure. Circular RNA may represent a potential new therapeutic strategy to attenuate the pathogenesis of cardiac diseases.Sustained cardiac hypertrophy accompanied by maladaptive cardiac remodelling represents an early event in the clinical course leading to heart failure. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. However, the molecular mechanisms that regulate cardiac hypertrophy are largely unknown. Here we show that a circular RNA (circRNA), which we term heart-related circRNA (HRCR), acts as an endogenous miR-223 sponge to inhibit cardiac hypertrophy and heart failure. miR-223 transgenic mice developed cardiac hypertrophy and heart failure, whereas miR-223-deficient mice were protected from hypertrophic stimuli, indicating that miR-223 acts as a positive regulator of cardiac hypertrophy. We identified ARC as a miR-223 downstream target to mediate the function of miR-223 in cardiac hypertrophy. Apoptosis repressor with CARD domain transgenic mice showed reduced hypertrophic responses. Further, we found that a circRNA HRCR functions as an endogenous miR-223 sponge to sequester and inhibit miR-223 activity, which resulted in the increase of ARC expression. Heart-related circRNA directly bound to miR-223 in cytoplasm and enforced expression of HRCR in cardiomyocytes and in mice both exhibited attenuated hypertrophic responses. These findings disclose a novel regulatory pathway that is composed of HRCR, miR-223, and ARC. Modulation of their levels provides an attractive therapeutic target for the treatment of cardiac hypertrophy and heart failure.
引用
收藏
页码:2602 / U24
页数:11
相关论文
共 50 条
  • [21] A high-throughput drug screening identifies luteolin as a therapeutic candidate for pathological cardiac hypertrophy and heart failure
    Wang, Zhenya
    Shi, Wei
    Wu, Taibo
    Peng, Tian
    Wang, Xiaoming
    Liu, Shuaiyang
    Yang, Zifeng
    Wang, Jia
    Li, Peng-Long
    Tian, Ruifeng
    Hong, Ying
    Yang, Hailong
    Bai, Lan
    Hu, Yufeng
    Cheng, Xu
    Li, Hongliang
    Zhang, Xiao-Jing
    She, Zhi-Gang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [22] Ouabain prevents pathological cardiac hypertrophy and heart failure through activation of phosphoinositide 3-kinase a in mouse
    Wu, Jian
    Li, Daxiang
    Du, Lingling
    Baldawi, Mustafa
    Gable, Marjorie E.
    Askari, Amir
    Liu, Lijun
    CELL AND BIOSCIENCE, 2015, 5
  • [23] Constitutive nitric oxide synthases in the heart from hypertrophy to failure
    Loyer, Xavier
    Heymes, Christophe
    Samuel, Jane-Lise
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2008, 35 (04) : 483 - 488
  • [24] Lingguizhugan decoction dynamically regulates MAPKs and AKT signaling pathways to retrogress the pathological progression of cardiac hypertrophy to heart failure
    Chen, Yao
    Li, Lin
    Hu, Cunyu
    Zhao, Xin
    Zhang, Peng
    Chang, Yanxu
    Shang, Ye
    Pang, Yafen
    Qian, Weiqiang
    Qiu, Xianzhe
    Zhang, Hongxia
    Zhang, Deqin
    Zhang, Shukun
    Li, Yuhong
    PHYTOMEDICINE, 2022, 98
  • [25] Resistin deletion protects against heart failure injury by targeting DNA damage response
    Zhao, Baoyin
    Bouchareb, Rihab
    Lebeche, Djamel
    CARDIOVASCULAR RESEARCH, 2022, 118 (08) : 1947 - 1963
  • [26] Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy
    Guo, Jian
    Mihic, Anton
    Wu, Jun
    Zhang, Yuemei
    Singh, Kaustabh
    Dhingra, Sanjiv
    Weisel, Richard D.
    Li, Ren-Ke
    EUROPEAN HEART JOURNAL, 2015, 36 (37) : 2530 - 2540
  • [27] Identification of TGF-13-related genes in cardiac hypertrophy and heart failure based on single cell RNA sequencing
    Huang, Kai
    Wu, Hao
    Xu, Xiangyang
    Wu, Lujia
    Li, Qin
    Han, Lin
    AGING-US, 2023, 15 (14): : 7187 - 7218
  • [28] Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress
    Oudit, Gavin Y.
    Kassiri, Zamaneh
    Zhou, Joyce
    Liu, Qiao C.
    Liu, Peter P.
    Backx, Peter H.
    Dawood, Fayez
    Crackower, Michael A.
    Scholey, James W.
    Penninger, Josef M.
    CARDIOVASCULAR RESEARCH, 2008, 78 (03) : 505 - 514
  • [29] Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo - An apoptosis-independent model of dilated heart failure
    De Windt, LJ
    Lim, HW
    Taigen, T
    Wencker, D
    Condorelli, G
    Dorn, GW
    Kitsis, RN
    Molkentin, JD
    CIRCULATION RESEARCH, 2000, 86 (03) : 255 - 263
  • [30] Circular RNA Expression Profiles in Plasma from Patients with Heart Failure Related to Platelet Activity
    Sun, Yeying
    Jiang, Xiaoli
    Lv, Yan
    Liang, Xinyue
    Zhao, Bingrui
    Bian, Weihua
    Zhang, Daolai
    Jiang, Jing
    Zhang, Chunxiang
    BIOMOLECULES, 2020, 10 (02)